HOUSTON, July 6, 2020 — Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), published in peer reviewed journal of Annals of Internal Medicine. Both patients were critically ill and intubated (one on ECMO). Both had failed Tociluzimab (Actemra, Roche) and had multiorgan failure. Patients received cell therapy under FDA Emergency Use IND for up to 3 doses. [Read more…]
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
CRISPR Therapeutics and Vertex Pharmaceuticals Have Been Awarded an FDA RMAT Designation for CTX001™ in the Treatment of Severe Hemoglobinopathies
CTX001 has received Orphan Drug Designation from the U.S. FDA for transfusion-dependent beta thalassemia and from the European Medicines Agency (EMA) for sickle cell disease and transfusion-dependent beta thalassemia
ZUG, Switzerland and Cambridge, MA, May 11, 2020 — CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. FDA RMAT designation to CTX001, an investigational, autologous, gene-edited hematopoietic stem cell therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). [Read more…]
In addition to the use of stem cells for the treatment of cancer and other chronic diseases, stem cell treatments for hips are being now showing great promise.
Throughout time and across the world, people have aged into delicacy, and ultimately, decline. While death is a natural part of the human condition – the end any organism can expect eventually – it sometimes comes sooner than it needs. Even when it doesn’t, decline makes life more difficult and the body less sound. This hard fact has made the possibility of stem cell treatments for hips and other parts of the body appealing. [Read more…]
Where do stem cells come from? Learn the basics of these “master cells” to better understand their therapeutic potential.
With large-scale trials underway using stem cell therapeutics to address the complications of COVID-19, these cells are receiving greater clinical attention than ever before in history. Currently, the Australian stem cell company (Mesoblast) is enrolling for a 300 person trial against COVID-19 complications and the American company (Athersys) is enrolling for a 400 person trial.
If succesful, these trials could forever alter the course of the current pandemic—as well as the future of stem cell therapeutics themselves.
In this article:
- An Introduction to Human Stem Cells
- Types of Stem Cells
- Where Do Stem Cells Come From?
- The Donation Process
- What Can Stem Cells Treat?
- Stem Cells for Testing New Drugs
- The Benefits of Stem Cell Transplant
- The Survival Rate of Stem Cell Therapy
RMAT designation reinforces clinical significance of investigational biologic product TTAX02 used during in-utero fetal surgical repair of spina bifida.
MIAMI, April 16, 2020 — TissueTech, Inc., the pioneer in the development and clinical application of regenerative human birth tissue products, announced today that the U.S. Food and Drug Administration (FDA) has granted their cryopreserved human umbilical cord investigational biologic product TTAX02 RMAT designation for the treatment of spina bifida in-utero.